"Secukinumab shows higher symptomatic improvement versus etanercept in psoriatic arthritis: comparative effectiveness up to 24 weeks assessed by Matching-Adjusted Indirect Comparison. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR-Latin America), 6th Latin America Conference, Sao Paulo, Brazil, Sept 2017." by Philip Mease

Presentation

Secukinumab shows higher symptomatic improvement versus etanercept in psoriatic arthritis: comparative effectiveness up to 24 weeks assessed by Matching-Adjusted Indirect Comparison. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR-Latin America), 6th Latin America Conference, Sao Paulo, Brazil, Sept 2017.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR-Latin America) (2017)

Philip Mease, Providence St. Joseph Health
et.al.

Link

Disciplines

Rheumatology

Publication Date

September, 2017

Citation Information

Philip Mease and et.al.. "Secukinumab shows higher symptomatic improvement versus etanercept in psoriatic arthritis: comparative effectiveness up to 24 weeks assessed by Matching-Adjusted Indirect Comparison. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR-Latin America), 6th Latin America Conference, Sao Paulo, Brazil, Sept 2017." The International Society for Pharmacoeconomics and Outcomes Research (ISPOR-Latin America) (2017)
Available at: http://works.bepress.com/philip-mease/217/